Mirza Ahmed, MD
Interventional Cardiology · London, KYNPI 1376653634
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,971 of the $19,927 with a category attached, or 65.1%. Angiodynamics, Inc. accounts for 88.7% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2021 at $8,221 and has fallen 94.6% since, to $442 in 2025.
Across 109 payments — averaging $182.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$18K
- Boston Scientific$321
- Novo Nordisk$281
- Merck$192
- Amgen$189
- Lilly USA, LLC$171
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,23111%
- Education$12,97165%
- Other$4,72524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $17,685 |
| Boston Scientific | 11 | $321 |
| Novo Nordisk | 14 | $281 |
| Merck | 9 | $192 |
| Amgen | 9 | $189 |
| Lilly USA, LLC | 4 | $171 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $115 |
| AstraZeneca | 7 | $108 |
| Pfizer | 6 | $97 |
| Boehringer Ingelheim | 2 | $87 |
| Baxter Healthcare | 3 | $81 |
| Edwards Lifesciences | 3 | $71 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Bayer | 2 | $42 |
| Abbott | 3 | $41 |
| Cook Medical LLC | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Novartis | 2 | $36 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| Exact Sciences | 1 | $23 |
| AbbVie | 1 | $21 |
| GSK | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Renalytix AI, Inc. | 1 | $20 |
| Osprey Medical Inc | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Inari Medical, Inc. | 1 | $15 |
| Preventice Services, LLC | 1 | $13 |
| Medtronic | 1 | $13 |
| EKOS Corporation | 1 | $12 |
| Biotronik Inc. | 1 | $11 |
| Veloxis Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVLT$9,600
- VenaCure EVLT$4,725
- VenaCure 1470 Pro$3,360
- ZEPBOUND$119
How this compares
$19,927 in reported general payments places this provider in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $28,908 |
| EliquisApixaban | 33 | $22,862 |
| MounjaroTirzepatide | 22 | $22,714 |
| Metoprolol Succinate | 151 | $1,398 |
| Nifedipine ErNifedipine | 53 | $810 |
| Rosuvastatin Calcium | 51 | $523 |
| Atorvastatin Calcium | 58 | $430 |
| Losartan Potassium | 38 | $315 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $271 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 39 | $208 |
| Amlodipine Besylate | 45 | $189 |
| Carvedilol | 29 | $186 |
| Valsartan | 12 | $182 |
| Pantoprazole Sodium | 14 | $153 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 21 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $281 | $28,90827 claims |
| PfizerEliquis | $97 | $22,86233 claims |
| Lilly USA, LLCMounjaro | $171 | $22,71422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in London
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
- Armaghan SoomroLexington$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.